Inactivating mutations in the tumour suppressor geneTP53are frequent in cancer. This Review provides a critical overview of reactivating p53 as a therapeutic strategy, describing preclinical and clinical compounds that re-establish the functions of wild-type p53 in tumours.
- Vladimir J. N. Bykov
- Sofi E. Eriksson
- Klas G. Wiman
